We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
PolyPeptide Group announces the exercise of the full over-allotment option
5 May 2021 - PolyPeptide Group AG ("PolyPeptide" or "the Group"), a global leader in peptide development and manufacturing, today announced that the Joint Global Coordinators have exercised in full the over-allotment option granted in connection with its Initial Public Offering (the "IPO") at the offer price of CHF 64 per share.
Read moreStock exchange listing
29 Apr 2021 - Today the PolyPeptide Group became a public company. Our shares are being traded on SIX, the Swiss Stock Exchange. What an exhilarating day! Today the PolyPeptide […]
Read morePolyPeptide Group appoints Raymond De Vré as new Chief Executive Officer
16 Feb 2021 - PolyPeptide Group, a global leader in peptide manufacturing and development, today announced the appointment of as its new Chief Executive Officer. He will succeed Jane Salik […]
Read morePolyPeptide News Flash, #1, 2021
28 Jan 2021 - Get to know Christelle Bobier, Director Global Engineering and Manufacturing Technology, in our newsletter. PolyPeptide Group maintained a strong and healthy pipeline that has gained a […]
Read moreTherapeutic indications for the PolyPeptide Group pipeline projects 2020
28 Jan 2021 - PolyPeptide Group is proud to report double-digit growth for its pipeline projects. PolyPeptide Group maintained a strong and healthy pipeline that has gained a significant growth […]
Read moreNew in-silico development tools support more efficient process design
8 Dec 2020 - The Polypeptide Group has developed a set of tools using Ypso-Proxima® software. They help make the most efficient choices at an early stage. The field of […]
Read morePolyPeptide News Flash, #3, 2020
17 Sep 2020 - The PolyPeptide Group is working on projects with clients developing peptide-based therapies and vaccines to combat COVID-19. As a Global Leader in Peptide Manufacturing and Development, […]
Read moreCapacity Expansion through Investment and Innovation
17 Sep 2020 - We have made considerable investments in scale capacities to satisfy the needs of our customers from early stage development to commercial production. Considering the continuous growth […]
Read moreMinimizing HCN in DIC/Oxyma-Mediated Amide Bond-Forming Reactions
15 Jun 2020 - Aiming at advancing protocols for safer, environmentally sensible peptide synthesis we report our findings with regard to the occurrence of hydrogen cyanide (HCN, prussic acid) in amide bond-forming reactions mediated by diisopropylcarbodiimide (DIC) and ethyl (hydroxyimino)cyanoacetate (Oxyma).[…]
Read more